{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:41:43Z","timestamp":1790116903288,"version":"4.0.1"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The evolution of anticoagulation therapy, from vitamin K antagonists to the advent of direct oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite improved safety demonstrated in pivotal trials and post-marketing observations, persistent concerns exist, particularly regarding bleeding risk and the absence of therapeutic indications in specific subgroups or clinical contexts. Factor XI (FXI) has recently emerged as a pivotal contributor to intraluminal thrombus formation and growth, playing a limited role in sealing vessel wall injuries. Inhibiting FXI presents an opportunity to decouple thrombosis from haemostasis, addressing concerns related to bleeding events while safeguarding against thromboembolic events. Notably, FXI inhibition holds promise for patients with end-stage renal disease or cancer, where clear indications for DOACs are currently lacking. Various compounds have undergone design, testing, and progression to phase 2 clinical trials, demonstrating a generally favourable safety and tolerability profile. However, validation through large-scale phase 3 trials with sufficient power to assess both safety and efficacy outcomes is needed. This review comprehensively examines FXI inhibitors, delving into individual classes, exploring their pharmacological properties, evaluating the latest evidence from randomized trials, and offering insights into future perspectives.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvae002","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:06:07Z","timestamp":1704870367000},"page":"245-258","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacological and clinical appraisal of factor XI inhibitor drugs"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-7242","authenticated-orcid":false,"given":"Giovanni","family":"Occhipinti","sequence":"first","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-7402","authenticated-orcid":false,"given":"Claudio","family":"Laudani","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-607X","authenticated-orcid":false,"given":"Marco","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Finocchiaro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Placido Maria","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-6176","authenticated-orcid":false,"given":"Denise Cristiana","family":"Faro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sara","family":"Mauro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Rochira","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agnello","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-3011","authenticated-orcid":false,"given":"Daniele","family":"Giacoppo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ammirabile","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Landolina","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Imbesi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sangiorgio","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2926-9428","authenticated-orcid":false,"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico\u2014San Marco\u201d, University of Catania , Catania 95123 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"2024052412211331100_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/107602960100700403","article-title":"The oral anticoagulant saga: past, present, and future","volume":"7","author":"Duxbury","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"2024052412211331100_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/01.CIR.89.1.432","article-title":"History of drugs for thrombotic disease. Discovery, development, and directions for the future","volume":"89","author":"Mueller","year":"1994","journal-title":"Circulation"},{"key":"2024052412211331100_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(05)76139-0","article-title":"The Nobel chronicles. 1943: henrik Carl Peter Dam (1895-1976); and Edward Adelbert Doisy (1893-1986)","volume":"353","author":"Raju","year":"1999","journal-title":"Lancet"},{"key":"2024052412211331100_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/000331975300400410","article-title":"Warfarin sodium derivative: (coumadin sodium); an intravenous hypoprothrombinemia-inducing agent","volume":"4","author":"Shapiro","year":"1953","journal-title":"Angiology"},{"key":"2024052412211331100_bib5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCRESAHA.112.264903","article-title":"Translational success stories: development of direct thrombin inhibitors","volume":"111","author":"Coppens","year":"2012","journal-title":"Circ Res"},{"key":"2024052412211331100_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024052412211331100_bib7","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct Oral Anticoagulant Use: a Practical Guide to Common Clinical Challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024052412211331100_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2024052412211331100_bib9","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2024052412211331100_bib10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of Factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"2024052412211331100_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC Review Topic of the Week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024052412211331100_bib12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI Inhibitors in Early Clinical Trials: a Meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"2024052412211331100_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1160\/TH08-04-0260","article-title":"Factor XI protein in human pancreas and kidney","volume":"100","author":"Cheng","year":"2008","journal-title":"Thromb Haemost"},{"key":"2024052412211331100_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1101\/sqb.2009.74.001","article-title":"Step-by-step evolution of vertebrate blood coagulation","volume":"74","author":"Doolittle","year":"2009","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2024052412211331100_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1538-7836.2009.03306.x","article-title":"Discordant fibrin formation in hemophilia","volume":"7","author":"Brummel Ziedins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2516.2000.00053.x","article-title":"Factor XI deficiency and its management","volume":"6","author":"Bolton","year":"2000","journal-title":"Haemophilia"},{"key":"2024052412211331100_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"2024052412211331100_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41569-023-00872-4","article-title":"Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale","volume":"20","author":"Gigante","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2024052412211331100_bib19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1055\/s-0041-1735971","article-title":"The association between Factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events","volume":"122","author":"Sharman Moser","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024052412211331100_bib20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"2024052412211331100_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of Factor XIa inhibitor drugs: JACC Review Topic of the Week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024052412211331100_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14728214.2023.2192923","article-title":"A review of emerging Factor XI inhibitors","volume":"28","author":"Elsheikh","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"key":"2024052412211331100_bib23","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway Factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"2024052412211331100_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"key":"2024052412211331100_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2024052412211331100_bib26","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2011-10-387134","article-title":"Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys","volume":"119","author":"Younis","year":"2012","journal-title":"Blood"},{"key":"2024052412211331100_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2019.1621838","article-title":"Pharmacokinetics and clinical pharmacology considerations of GalNAc(3)-conjugated antisense oligonucleotides","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2024052412211331100_bib28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2024052412211331100_bib29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/00003088-200645080-00003","article-title":"Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone","volume":"45","author":"Geary","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"2024052412211331100_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.omtn.2017.08.012","article-title":"Assessment of the Drug Interaction Potential of Unconjugated and GalNAc(3)-Conjugated 2'-MOE-ASOs","volume":"9","author":"Shemesh","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"2024052412211331100_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2024052412211331100_bib32","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","article-title":"Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know","volume":"127","author":"Foltz","year":"2013","journal-title":"Circulation"},{"key":"2024052412211331100_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","article-title":"Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe","volume":"48","author":"Yu","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2024052412211331100_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"2024052412211331100_bib35","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMoa2113194","article-title":"Abelacimab for prevention of venous thromboembolism. Reply","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052412211331100_bib36","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2024052412211331100_bib38","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric Inhibition as a New Mode of Action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"2024052412211331100_bib39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"2024052412211331100_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and Factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 First-In-Human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024052412211331100_bib42","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"2024052412211331100_bib43","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.3390\/ijms21155262","article-title":"Mechanisms of action for small molecules revealed by structural biology in drug discovery","volume":"21","author":"Li","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024052412211331100_bib44","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024052412211331100_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-022-00266-6","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a Factor XIa inhibitor","volume":"11","author":"Perera","year":"2022","journal-title":"Cardiol Ther"},{"key":"2024052412211331100_bib46","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib47","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"key":"2024052412211331100_bib48","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2024052412211331100_bib51","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","article-title":"First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects","volume":"84","author":"Perera","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2024052412211331100_bib52","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052412211331100_bib53","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral Factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"2024052412211331100_bib54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.12797","article-title":"Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity","volume":"13","author":"Chen","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2024052412211331100_bib55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20091007","article-title":"Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis","volume":"206","author":"Decrem","year":"2009","journal-title":"J Exp Med"},{"key":"2024052412211331100_bib56","doi-asserted-by":"crossref","first-page":"e0004298","DOI":"10.1371\/journal.pntd.0004298","article-title":"In vitro mode of action and anti-thrombotic activity of Boophilin, a multifunctional Kunitz protease inhibitor from the midgut of a tick vector of Babesiosis, Rhipicephalus microplus","volume":"10","author":"Assump\u00e7\u00e3o","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2024052412211331100_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbrc.2009.12.177","article-title":"Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa\/tissue factor from the blood-feeding nematode Ancylostoma caninum","volume":"392","author":"Li","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2024052412211331100_bib58","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2013-08-517474","article-title":"Desmolaris, a novel Factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo","volume":"122","author":"Ma","year":"2013","journal-title":"Blood"},{"key":"2024052412211331100_bib59","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of Factors XIa and XIIa during cardiopulmonary bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024052412211331100_bib60","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2024052412211331100_bib61","doi-asserted-by":"crossref","first-page":"e022198","DOI":"10.1161\/JAHA.121.022198","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024052412211331100_bib62","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2023.2291865","article-title":"Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management","volume":"22","author":"Laudani","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2024052412211331100_bib63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2024052412211331100_bib64","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral Factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"2024052412211331100_bib65","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 Update: a Report From the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"2024052412211331100_bib66","doi-asserted-by":"crossref","first-page":"e0209687","DOI":"10.1371\/journal.pone.0209687","article-title":"Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"2024052412211331100_bib67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"key":"2024052412211331100_bib68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024052412211331100_bib69","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jacc.2023.07.025","article-title":"Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review","volume":"82","author":"Greco","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024052412211331100_bib70","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"2024052412211331100_bib71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"2024052412211331100_bib72","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin Dial"},{"key":"2024052412211331100_bib73","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin Kidney J"},{"key":"2024052412211331100_bib74","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024052412211331100_bib75","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"2024052412211331100_bib76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"2024052412211331100_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae002\/56431912\/pvae002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/3\/245\/57701429\/pvae002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/3\/245\/57701429\/pvae002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T14:50:29Z","timestamp":1716562229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/3\/245\/7513760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,9]]},"published-print":{"date-parts":[[2024,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae002","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,1,9]]}}}